➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Boehringer Ingelheim
AstraZeneca
Moodys
McKesson

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 8,623,830

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,623,830
Title:Compositions containing .alpha.-1-antitrypsin and methods for use
Abstract: Methods and compositions for treating patients (e.g., patients who are insulin resistant, patients who have diabetes, or are at risk for developing diabetes) are disclosed herein. The methods can include administration of an a1 antitrypsin (AAT) polypeptide or an agent, such as a nucleic acid molecule or organic compound, that promotes the expression or activity of a1-antitrypsin.
Inventor(s): Flier; Jeffrey (Newton, MA), Koulmanda; Maria (Brookline, MA), Strom; Terry B. (Brookline, MA)
Assignee: Beth Israel Deaconess Medical Center, Inc. (Boston, MA) The General Hospital Corporation (Boston, MA)
Application Number:12/441,064
Patent Claims:see list of patent claims

Details for Patent 8,623,830

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial Beth Israel Deaconess Medical Center, Inc. (Boston, MA) The General Hospital Corporation (Boston, MA) 2026-09-12 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Beth Israel Deaconess Medical Center, Inc. (Boston, MA) The General Hospital Corporation (Boston, MA) 2026-09-12 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial Beth Israel Deaconess Medical Center, Inc. (Boston, MA) The General Hospital Corporation (Boston, MA) 2026-09-12 RX Orphan search
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 001 2001-11-14   Start Trial Beth Israel Deaconess Medical Center, Inc. (Boston, MA) The General Hospital Corporation (Boston, MA) 2026-09-12 RX search
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 002 2001-11-14   Start Trial Beth Israel Deaconess Medical Center, Inc. (Boston, MA) The General Hospital Corporation (Boston, MA) 2026-09-12 RX search
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 003 2001-11-14   Start Trial Beth Israel Deaconess Medical Center, Inc. (Boston, MA) The General Hospital Corporation (Boston, MA) 2026-09-12 RX search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial Beth Israel Deaconess Medical Center, Inc. (Boston, MA) The General Hospital Corporation (Boston, MA) 2026-09-12 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Merck
Baxter
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.